share_log

永泰生物-B(06978.HK)：迪诺仑赛注射液一期临床试验首例患者入组

Yongtai Bio-B (06978.HK): The first patient enrolled in the phase I clinical trial of Dinorancel injection

Gelonghui Finance ·  Nov 7, 2023 04:33

Gelonghui November 7th 丨Yongtai Bio-B (06978.HK) announced that on November 7, 2023, the company completed the first patient enrolled in the phase I clinical trial of Dinoruncet Injection (“DCI”) in China, marking a milestone in the development of the products being developed by the Group. DCI (formerly RC19D2, CAR-T-19-D2, and CAR-T-19-DNR) targets CD19 antigen and antagonizes TGF-ßesProteins of downstream signaling pathways are used as injections to treat patients with recurrent and refractory diffuse large B-cell lymphoma (“DLBCL”). The goal of this injection is to solve the pain points of chimeric antigen receptor T cells (“CAR-T cells”) for the treatment of solid tumors that are not durable enough, the treatment effect is poor, and the prevention of tumor recurrence. According to DCI's clinical trial progress, target patient recruitment is expected to be completed by the end of 2024, and preliminary analysis and results will be announced in the first half of 2025.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment